Display options
Cite
Li FF, Jiang L, Fu L, et al. Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial. Diabetes Ther. 2016;8(1):177-187doi: 10.1007/s13300-016-0222-7.
Li, F. F., Jiang, L., Fu, L., Zhu, H. H., Zhou, P., Zhang, D., Su, X. F., Wu, J. D., Ye, L., & Ma, J. H. (2017). Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial. Diabetes therapy : research, treatment and education of diabetes and related disorders, 8(1), 177-187. https://doi.org/10.1007/s13300-016-0222-7
Li, Feng-Fei, et al. "Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 8,1 (2017): 177-187. doi: https://doi.org/10.1007/s13300-016-0222-7
Li FF, Jiang L, Fu L, Zhu HH, Zhou P, Zhang D, Su XF, Wu JD, Ye L, Ma JH. Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial. Diabetes Ther. 2017 Feb;8(1):177-187. doi: 10.1007/s13300-016-0222-7. Epub 2016 Dec 19. PMID: 27995593; PMCID: PMC5306121.
Copy Download .nbib Format: NLM
Share it on

Diabetes Ther. 2017 Feb;8(1):177-187. doi: 10.1007/s13300-016-0222-7. Epub 2016 Dec 19.

Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Feng-Fei Li, Lanlan Jiang, Liyuan Fu, Hong-Hong Zhu, Peihua Zhou, Danfeng Zhang, Xiao-Fei Su, Jin-Dan Wu, Lei Ye, Jian-Hua Ma

Affiliations

  1. Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
  2. National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore.
  3. Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. [email protected].

PMID: 27995593 PMCID: PMC5306121 DOI: 10.1007/s13300-016-0222-7

Abstract

INTRODUCTION: The objective of this study was to investigate the effect of adding exenatide to continuous subcutaneous insulin infusion (CSII) therapy on the precise insulin doses required by type 2 diabetic patients to maintain glycemic control.

METHODS: This was a single-center, randomized, controlled, open-label trial. Uncontrolled T2D patients were recruited between March 2010 and November 2011 at Nanjing First Hospital, China. Subjects were randomly assigned (1:1) to either an exenatide add-on to CSII group or a CSII therapy only (i.e., control) group (n = 18, respectively) for 5 weeks. Patients were subjected to 3 days of continuous glucose monitoring (CGM) during the screening period and after therapy. The precise insulin doses, the times taken by the patients to achieve euglycemic control, and the mean amplitude of glycemic excursion (MAGE) at the endpoint were compared between the two groups. The primary endpoint was precise insulin dose differences between groups from baseline to the endpoint.

RESULTS: A total of 36 subjects were admitted as inpatients. Patients in the exenatide add-on therapy group needed less insulin titration time to achieve glycemic control (3.67 ± 1.33 vs. 4.78 ± 1.00 days, P = 0.028) and significantly lower bolus insulin doses than the control group at the endpoint (total bolus, 0.13 ± 0.03 vs. 0.17 ± 0.04 U/kg, P = 0.02, breakfast bolus, 0.05 ± 0.01 vs. 0.06 ± 0.01 U/kg, P = 0.01, lunch bolus, 0.04 ± 0.01 vs. 0.06 ± 0.01 U/kg, P = 0.01, dinner bolus, 0.04 ± 0.01 vs. 0.05 ± 0.01 U/kg, P = 0.01, respectively). Moreover, the CGM data showed that patients in the exenatide add-on therapy group exhibited a significant reduction in MAGE as compared to the control group (2.96 ± 1.14 vs. 4.21 ± 1.39 mmol/L, P = 0.012).

CONCLUSION: Our data suggest that adding exenatide therapy to CSII therapy leads to an improvement in glycemic excursions and the use of smaller bolus insulin doses.

TRIAL REGISTRATION: Chinese Clinical Trial Registry identifier, ChiCTR-PPR-15007045.

Keywords: Exenatide; Glycemic variations; Insulin doses; Type 2 diabetes

References

  1. Pharmacology. 2010;86(1):44-57 - PubMed
  2. Postgrad Med. 2013 May;125(3):47-57 - PubMed
  3. Diabetes Care. 2015 Jan;38(1):140-9 - PubMed
  4. Int J Obes Relat Metab Disord. 2001 Dec;25 Suppl 5:S42-7 - PubMed
  5. Diabetes Care. 2014 Sep;37(9):2500-7 - PubMed
  6. Diabetes Care. 2004 May;27(5):1028-32 - PubMed
  7. Diabetes Care. 1997 Sep;20(9):1353-6 - PubMed
  8. Arch Intern Med. 2001 Feb 12;161(3):397-405 - PubMed
  9. Trials. 2016 Mar 24;17 :160 - PubMed
  10. Ann Intern Med. 2011 Jan 18;154(2):103-12 - PubMed
  11. Diabetes Care. 2012 Jun;35(6):1364-79 - PubMed
  12. J Pharm Pharm Sci. 2012;15(1):1-30 - PubMed
  13. Curr Med Res Opin. 2008 Jan;24(1):275-86 - PubMed
  14. Diabetes Obes Metab. 2007 Nov;9(6):853-8 - PubMed
  15. Rev Diabet Stud. 2009 Winter;6(4):247-59 - PubMed
  16. Diabetes Care. 1999 Feb;22(2):233-40 - PubMed
  17. Diabetes. 2005 Jun;54(6):1615-25 - PubMed
  18. Int J Clin Pract. 2010 Jul;64(8):1121-9 - PubMed
  19. Pharmacotherapy. 2016 Aug;36(8):893-905 - PubMed
  20. Sci Rep. 2015 Nov 26;5:16968 - PubMed
  21. Diabetes Technol Ther. 2011 Feb;13(2):143-8 - PubMed
  22. JAMA. 2007 Jul 11;298(2):194-206 - PubMed
  23. Diabetes Technol Ther. 2013 Sep;15(9):738-43 - PubMed
  24. Diabetes Obes Metab. 2014 Oct;16(10):900-9 - PubMed
  25. Diabetes Care. 2004 Nov;27(11):2597-602 - PubMed
  26. Diabetes Ther. 2015 Sep;6(3):239-56 - PubMed
  27. Diabetes Technol Ther. 2011 Dec;13(12):1261-3 - PubMed
  28. Diabetes Metab Syndr Obes. 2012;5:29-41 - PubMed
  29. Diabetes Care. 2016 Jun;39(6):973-81 - PubMed
  30. Diabetes Care. 2009 Jan;32(1):193-203 - PubMed
  31. Lancet. 2014 Dec 20;384(9961):2228-34 - PubMed
  32. Int J Endocrinol. 2015;2015:903524 - PubMed
  33. J Clin Lab Anal. 2016 Nov 17;:null - PubMed
  34. Diabetes Metab Res Rev. 2011 Sep;27(6):528-42 - PubMed
  35. Diabetes Obes Metab. 2016 Sep;18(9):882-91 - PubMed
  36. Diabetes Obes Metab. 2011 Feb;13(2):99-117 - PubMed
  37. Curr Diab Rep. 2016 May;16(5):44 - PubMed
  38. Lancet. 2008 May 24;371(9626):1725-6 - PubMed
  39. Lancet. 2008 May 24;371(9626):1753-60 - PubMed
  40. J Diabetes Res. 2016;2016:1028945 - PubMed
  41. Curr Diab Rep. 2015 Jun;15(6):602 - PubMed
  42. Diabetes Care. 2001 Nov;24(11):1858-62 - PubMed

Publication Types